Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome

Back

ESC Professional Premium Access

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome

Session: What’s new on lipids and diabetes in acute coronary syndrome

Topic: Thrombosis, Platelets, and Coagulation

Speaker: Doctor E. Ziogos (Baltimore, US)

Event: ESC Congress 2022

Congress Presentation

About the speaker

Doctor Efthymios Ziogos

The Johns Hopkins University School of Medicine, Baltimore (United States of America)

0 follower

5 more presentations in this session

Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

Speaker: Professor P. Steg (Paris, FR)

Quality matters: low-density lipoprotein electronegativity but not quantity determines mortality risk in acute coronary syndromes

Speaker: Doctor S. Kraler (Zurich, CH)

Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina - a prospective Norwegian cohort

Speaker: Doctor G. Svingen (Bergen, NO)

Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability.

Speaker: Professor J. Badimon (New York, US)

Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction.

Speaker: Doctor F. Trombara (Milan, IT)

Access the full session

What’s new on lipids and diabetes in acute coronary syndrome

Speakers: Doctor E. Ziogos, Professor P. Steg, Doctor S. Kraler, Doctor G. Svingen, Professor J. Badimon...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome

About the speaker

Doctor Efthymios Ziogos

5 more presentations in this session

Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

Quality matters: low-density lipoprotein electronegativity but not quantity determines mortality risk in acute coronary syndromes

Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina - a prospective Norwegian cohort

Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability.

Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction.

Access the full session

What’s new on lipids and diabetes in acute coronary syndrome

About the event

ESC Congress 2022

ESC 365 is supported by